These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35942695)

  • 41. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D.
    Abbas Z; Saad M; Asim M; Abbas M; Samejo SA
    Turk J Gastroenterol; 2020 Feb; 31(2):136-141. PubMed ID: 32141822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
    Dietz-Fricke C; Tacke F; Zöllner C; Demir M; Schmidt HH; Schramm C; Willuweit K; Lange CM; Weber S; Denk G; Berg CP; Grottenthaler JM; Merle U; Olkus A; Zeuzem S; Sprinzl K; Berg T; van Bömmel F; Wiegand J; Herta T; Seufferlein T; Zizer E; Dikopoulos N; Thimme R; Neumann-Haefelin C; Galle PR; Sprinzl M; Lohse AW; Schulze Zur Wiesch J; Kempski J; Geier A; Reiter FP; Schlevogt B; Gödiker J; Hofmann WP; Buggisch P; Kahlhöfer J; Port K; Maasoumy B; Cornberg M; Wedemeyer H; Deterding K
    JHEP Rep; 2023 Apr; 5(4):100686. PubMed ID: 37025462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of hepatitis delta and HIV infection.
    Soriano V; de Mendoza C; Treviño A; Ramos-Rincón JM; Moreno-Torres V; Corral O; Barreiro P
    Liver Int; 2023 Aug; 43 Suppl 1():108-115. PubMed ID: 35748639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
    Zhang Z; Ni Y; Lempp FA; Walter L; Mutz P; Bartenschlager R; Urban S
    J Hepatol; 2022 Oct; 77(4):957-966. PubMed ID: 35636579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
    Asselah T
    Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of hepatitis delta: Need for novel therapeutic options.
    Abbas Z; Abbas M
    World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the Phase III MYR301 trial of bulevirtide.
    Buti M; Wedemeyer H; Aleman S; Chulanov V; Morozov V; Sagalova O; Stepanova T; Gish RG; Lloyd A; Kaushik AM; Suri V; Manuilov D; Osinusi AO; Flaherty JF; Lampertico P
    J Hepatol; 2024 Jul; ():. PubMed ID: 39009085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic hepatitis D-What is changing?
    Yardeni D; Heller T; Koh C
    J Viral Hepat; 2022 Apr; 29(4):240-251. PubMed ID: 35122369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Delta hepatitis: Epidemiology, diagnostic, natural history and treatment].
    Loureiro D; Castelnau C; Bed CM; Asselah T
    Rev Med Interne; 2022 Mar; 43(3):160-169. PubMed ID: 34799189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of Delta Hepatitis: Today and in the Future - A review.
    Bahcecioglu IH; Sahin A
    Infect Dis (Lond); 2017 Apr; 49(4):241-250. PubMed ID: 28092214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.
    Di Marco V; Giacchino R; Timitilli A; Bortolotti F; Crivellaro C; Calzia R; Iannuzzi C; Prestileo T; Vajro P; Nebbia G; Stringhi C; Rosina F; Biassoni D; Callea F; Rizzetto M; Craxi A
    J Viral Hepat; 1996 May; 3(3):123-8. PubMed ID: 8871870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
    Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bulevirtide: First Approval.
    Kang C; Syed YY
    Drugs; 2020 Oct; 80(15):1601-1605. PubMed ID: 32926353
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ergosterol peroxide blocks HDV infection as a novel entry inhibitor by targeting human NTCP receptor.
    Chiou WC; Lyu YS; Hsia TL; Chen JC; Lin LC; Chang MF; Hsu MS; Huang C
    Biomed Pharmacother; 2024 Jan; 170():116077. PubMed ID: 38154274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).
    Wranke A; Pinheiro Borzacov LM; Parana R; Lobato C; Hamid S; Ceausu E; Dalekos GN; Rizzetto M; Turcanu A; Niro GA; Lubna F; Abbas M; Ingiliz P; Buti M; Ferenci P; Vanwolleghem T; Hayden T; Dashdorj N; Motoc A; Cornberg M; Abbas Z; Yurdaydin C; Manns MP; Wedemeyer H; Hardtke S;
    Liver Int; 2018 May; 38(5):842-850. PubMed ID: 28963781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.